Chugai Pharmaceutical (OTCMKTS:CHGCY) Releases Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) issued its quarterly earnings results on Tuesday. The company reported $0.27 earnings per share for the quarter, Zacks reports. The firm had revenue of $2.54 billion during the quarter, compared to the consensus estimate of $2.29 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%.

Chugai Pharmaceutical Stock Performance

CHGCY opened at $20.98 on Thursday. Chugai Pharmaceutical has a 1-year low of $18.33 and a 1-year high of $34.84. The firm has a 50-day moving average price of $20.76 and a two-hundred day moving average price of $24.58. The stock has a market capitalization of $69.05 billion, a PE ratio of 22.80 and a beta of 0.60.

Analysts Set New Price Targets

Several research analysts recently issued reports on CHGCY shares. Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.